The Medicines Company’s partnered drug uses RNA interference to tackle stubbornly high LDL cholesterol.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Research progress on non-protein-targeted drugs for cancer therapy
Journal of Experimental & Clinical Cancer Research Open Access 14 March 2023
-
Therapeutic siRNA: State-of-the-Art and Future Perspectives
BioDrugs Open Access 23 August 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sheridan, C. PCSK9-gene-silencing, cholesterol-lowering drug impresses. Nat Biotechnol 37, 1385–1387 (2019). https://doi.org/10.1038/s41587-019-0351-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0351-4
This article is cited by
-
Research progress on non-protein-targeted drugs for cancer therapy
Journal of Experimental & Clinical Cancer Research (2023)
-
Advances in siRNA delivery approaches in cancer therapy: challenges and opportunities
Molecular Biology Reports (2023)
-
Therapeutic siRNA: State-of-the-Art and Future Perspectives
BioDrugs (2022)
-
Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
PharmacoEconomics (2020)